• About us
  • Research
  • Pipeline
  • Investment
  • News
Menu
  • About us
  • Research
  • Pipeline
  • Investment
  • News
  • EN
  • ES
Menu
  • EN
  • ES
Contact
  • About us
  • Investment
  • Pipeline
  • Research
  • News
  • Contact
  • EN
  • ES
Menu
  • About us
  • Investment
  • Pipeline
  • Research
  • News
  • Contact
  • EN
  • ES

A new path for neurodegenerative diseases

Investigación

Desarrollamos terapias génicas innovadoras para enfermedades neurodegenerativas mediante un mecanismo de acción multifuncional
Our therapy

Our roadmap has been validated by the AEMPS

Pipeline

A radical new approach
OUR PIPELINE

A new path for neurodegenerative diseases

Equipo científico

Equipo científico integrado por investigadores con más de 30 años de experiencia en neurociencia
ABOUT US

Research

We’re pioneering innovative gene therapies for neurodegenerative diseases through a multifactorial mechanism of action

Pipeline

A radically new approach with a significant impact on neurodegenerative diseases

Scientific Team

A scientific team added by researchers with over 30 years of expertise in neuroscience

Tetraneuron

Tetraneuron is a biotech company focused on novel gene therapies for neurodegenerative diseases

Based in Madrid and Valencia, Tetraneuron emerges as a spin-off from the Cajal Institute, affiliated with the Spanish National Research Council (CSIC)

ABOUT US

Nuestra historia

2023

New strategic alliances in Parkinson and aging

2022

Pre-IND meeting with the FDA

2021

Beginning of the preclinical regulatory phase

2020

Methode validation of TET-101

2019

Analysis of biological processes modulated by E2F4DN

2018

Validation of the Leading Compound

2017

Validation of the Leading Compound

2016

Identification of the Leading Compound

2015

Validation of the therapeutical target E2F4DN

2014

Beginning of the proof of concept

2013

Identification of the therapeutical target E2F4

2012

Tetraneuron was founded

Scientific research areas

Tetraneuron focuses its research on E2F4, a protein involved in regulating multiple brain pathways

We’re in the process of developing gene therapies aimed at addressing neurodegenerative conditions. These treatments have been devised to reinstate biological processes that have been impacted by the pathogenic phosphorylation of E2F4.

FIND OUT MORE

Multifactorial gene therapy Gene therapy

Our gene therapy based on E2F4DN is a promising approach for Alzheimer’s disease

More information

Early diagnosis biomarker

A method to ascertain the early risk of developing Alzheimer’s disease

More information

Neurodegenerative diseases

We introduce a profoundly innovative approach that holds the promise of transformative impact on brain health

More information

Scientific papers

Loading...

E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging (2022)

Leer más

A Mutant Variant of E2F4 Triggers Multifactorial Therapeutic Effects in 5xFAD Mice (2022)

Leer más

E2F4 as a single multifactorial target against Alzheimer’s disease (2021)

Leer más
VER TODOS

Our team

The scientific team has members with over 30 years of experience in neuroscience, along with executives from biopharmaceutical companies as partners.

Álvaro Pascual-Leone. MD.PhD

Scientific Board Member

Teodoro del Ser. MD. PhD

Scientific Board Member

José M. Frade. PhD

Scientific Director and co-Founder

Mari Carmen Álvarez. PhD

Managing Director

Mar Municio. PhD

R&D Director

Noelia López Sánchez. PhD

Technical Director

David Mor

Board Member

Cristina Sánchez Puelles. PhD

Senior Researcher

Morgan Ramón Landrau

Researcher

Alberto Garrido

Laboratory Technician

Vanesa Cano

Laboratory Technician

Marika Russo. PhD

Strategic Advisor

Alonso Fernández Nistal, PhD

Strategic Advisor

Ángel Lucio Pereira

Strategic Advisor

Irene Camacho

PhD. Student

CONTACT

Latest news at Tetraneuron

TETRANEURON

Check out our participation in the launch of #ComunidadDesafia! ?

We’re excited to be part of this dynamic community and look forward to the opportunities and collaborations ahead.

hashtag#YosoyDesafia
hashtag#ICEX

TETRANEURON

We had the privilege of attending the EMEA Summit as part of the JLabs family. ?✨

Johnson & Johnson Innovation – JLABS is a global life science network offering startups like ours access to expertise, a vibrant community, essential industry connections, and comprehensive entrepreneurial programs.

Being a part of this dynamic network accelerates our mission and amplifies our impact in the life sciences sector.??

TETRANEURON

Yesterday, we had an inspiring partner meeting at TETRANEURON , reaffirming our commitment to pioneering innovative gene therapies for neurodegenerative diseases. We extend our gratitude to our partners for their ongoing support. Together, we are making a difference!? #GeneTherapy #NeurodegenerativeDiseases #Innovation#Tetraneuron

TETRANEURON

? Exciting News! ? We’re thrilled to announce that we’ll be attending the RESI Europe conference in Barcelona on June 19th! Our team is excited to present our innovative project to international investors. Let’s connect and explore opportunities at RESI Europe. See you in Barcelona! ? #RESIEurope #Barcelona #Innovation #Investment #Networking

TETRANEURON

https://www.linkedin.com/posts/tetraneuron_tetraneuron-genetherapy-activity-7183463740216885248-vUp3

TETRANEURON

Embracing Change in 2024: We’re giving our website a fresh new look! Join us on this exciting journey to stay in the loop with all things Tetraneuron. Don’t miss out on the latest from Tetraneuron ? https://tetraneuron.com #TetraneuronUpdates #genetherapy

TETRANEURON

Last week, we had a really interesting session with our SAB Member Alvaro Pascual-Leone. Definitely, we have a lot of promising options to explore for our therapy now. Big thanks to Alvaro for sharing his talent with us! #genetherapy #Alzheimer #innovation #braindiseases

TETRANEURON

?? BIG NEWS! ???? We’re proud to announce a major milestone for TETRANEURON ! Our new corporate headquarters in Madrid is officially open, marking a significant step in our journey. ? . This dynamic space, in the heart of Madrid, has been designed to inspire collaboration, innovation, and growth towards developing life-changing gene therapies for neurodegenerative diseases. Join us on this incredible path at our stunning location: ? C/Velázquez 154, Madrid. ✨ We can’t wait to welcome you to our new space! ? #Tetraneuron #genetherapy #innovation #bignews

TETRANEURON

Fascinating piece by Expansión discussing the power of patents in companies like TETRANEURON . We’re all about robust IP for every innovation we craft? Thank you, Alive comunicación! ? #patents #genetherapy

TETRANEURON

We were delighted to have the opportunity to speak at #Biozell‘s #InvestorDay. Such events are pivotal in highlighting the innovation within the Spanish biotech sector. It was a pleasure to share the stage with other remarkable projects! #bioval #tetraneuron #alzheimer #genetherapy

TETRANEURON

Excited to welcome amazing investors like Biozell! ? Mark your calendar for October 17th. During the Investor’s Day, they will present their ongoing ventures and brand-new investment possibilities. We’re thrilled to showcase our project at this event. Don’t miss this opportunity to join it! #investment #alzheimer #genetherapy

TETRANEURON

Great day at #BioRNConference, Next-Generation Cell and Gene Therapies. #genetherapy #alzheimer

TETRANEURON

It was a pleasure attending the event “CERCO AL ALZHEIMER” at the Universidad Europea of Madrid. Our Scientific Advisor, Teodoro Del Ser Quijano, led an engaging discussion on therapeutic advancements and their current status. A remarkable event during the #Alzheimer‘s month 2023 #Alzheiemer #genetherapy

TETRANEURON

Meet us at #BIOSPAIN2023 in Barcelona ! Just a few days left to interact with experts, companies and investors from all over the world. Find our colleagues Maria del Mar Municio, Ph.D and M.Carmen Alvarez Abril at the partnering area. See you there! #Alzheimer #genetherapy

TETRANEURON

Exciting News! Join us at #IBRO2023 Conference. Our colleagues Cristina Sánchez-Puelles, PhD and Morgan Ramón Landreau will be presenting our amazing research on Alzheimer’s Disease. Visit us! ?Poster B28 ?Poster B03 #genetherapy #Tetraneuron #alzheimer

TETRANEURON

Great news! Congratulations to Maria del Mar Municio, Ph.D for her incorporation as R&D Director at TETRANEURON .Undoubtedly, her experience and leadership will further drive the innovation and development of the company. #Tetraneuron #Innovation #Leadership #alzheimer #genetherapy

TETRANEURON

Delighted by the industry’s progress! ? Yet, Alzheimer’s Drug Discovery Foundation reminds us to explore diverse pathways for more effective treatments. Our promising therapy targets key areas to make a difference. #Alzheimers #genetherapy #Tetraneuron

TETRANEURON

Muchas gracias #Valenciaplaza por haceros eco de esta importante noticia para #Tetraneuron Estamos encantados de contar con #Biozellventures como nuevo socio y contar con el enorme talento y experiencia de Angela Perez y su equipo. ¡Seguimos! ????? #genetherapy #alzheimersdisease #advancedtherapies #parkinson #biotech

TETRANEURON

Muchas gracias #Mendelbrain por haceros eco de esta importante noticia para #Tetraneuron ¡Seguimos! #terapiagenica #genetherapy #cns #snc #alzheimers #parkinson #aging #innovation #biotech #advancedtherapies

TETRANEURON

A new day in #AAIC23

TETRANEURON

Great news!? Biozell Ventures, the investment arm of BIOHUB VLC, is betting on Tetraneuron’s new gene therapy for Alzheimer’s disease. Please join us in welcoming our newest investors to the Tetraneuron family! #alzheimer #genetherapy

TETRANEURON

A new day in #AAIC2023!

TETRANEURON

The Alzheimer’s Association®International Conference (AAIC)- the most relevant conference on #alzheimer– starts next Sunday, 16 July, in Amsterdam! The Tetraneuron team is looking forward to joining researchers and clinicians to discuss the latest advances in the field. Several team members will present a poster during the event! – José María Frade. Scientific Director – Cristina Sánchez-Puelles, PhD. Senior Researcher – Morgan Ramón Landreau. Researcher Visit our posters or meet the team to learn more about our therapy TET-101. See you in #AAIC2023! #Tetraneuron #alzheimer #genetherapy

Collaborating Institutions

csic-1
instituto_cajal
incliva-logo
hospital-universitario-la-princesa
amsterdan-umc
funcacion-cien

Would you like to know more about Tetraneuron?

We invite you to join this new path for neurodegenerative diseases

CONTACT

A new path for neurodegenerative diseases

Contact

VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia

MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid

Ⓒ 2023 Tetraneuron S.L. All Rights Reserved

  • Cookies policy
  • Legal disclaimer
  • Cookies policy
  • Legal disclaimer
Cookie Notice
The website of TETRANEURON S.L. uses its own and third-party cookies for functional purposes (allow web browsing), to optimize browsing and personalize it according to your preferences as well as to show you advertising based on your browsing profile (e.g. pages visited). Click HERE for more information. You can accept all cookies by pressing the “ACCEPT” button or reject their use by pressing the “DECLINE” button.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}

Contact

Online contact form

TETRANEURON S.L processes your personal data in order to be able to manage the queries you ask us. You can exercise your rights of access, rectification, deletion, opposition, portability and limitation through our email info@tetraneuron.com. For more information you can access our Privacy Policy

VALENCIA
BIOHUB VLC
Travesía s/n 15 E Base 5,
46024 Valencia

MADRID
C/ Velázquez, 154 – Pta Baja Izda A , 28002 Madrid